Últimas noticias sobre Compass Pathways (NASDAQ:CMPS) Bolsa

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Here's the major earnings before the open tomorrow

COMPASS Pathways ADS GAAP EPS of -$0.56 in-line

Cash and cash equivalents were $207M as of September 30, 2024, vs. $220.2M as of December 31, 2023. "Ensuring the success of our lead COMP360 progr...

Compass Pathways reports Q3 EPS (56c), consensus (57c)

Cash position at September 30, 2024, is expected to be sufficient to fund operating expenses and capital expenditure requirements at least into 202...

Compass Pathways sees 2024 operating net cash use $114M-$120M

COMPASS Pathways falls after layoffs amid pipeline reset

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, an acquisi...

Rising High: Compass Pathways reports Q3 earnings

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Microsoft (MSFT) reported better-than-...

Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz

COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript

Compass Pathways Plc ( ($CMPS) ) has released its Q3 earnings. Here is a breakdown of the information Compass Pathways Plc presented to its investo...

Compass Pathways Focuses on Key Psilocybin Program

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on COMPASS Pathways (CMPS – Research Report). The associated price target remains t...

Strategic Foresight and Proactive Measures Underpin Buy Rating for COMPASS Pathways

ABEV

AGIO

ALGM

ALNY

AMKBY

APTV

ARGX

ATEC

ATGFF

AVNT

BALL

BAND

BBVA

BIIB

BNPQF

CANN

CCRD

CIFR

CMCSA

CMPS

CPSH

CRON

CVSI

DFIN

DINO

FFNTF

FLWS

FNMA

GNRC

GPRE

GTBIF

IDCC

IDXX

INSM

ISNPY

ITRI

LMND

MSFT

NVDA

PTON

RBLX

RIVN

ROOT

SBUX

SHFS

SKYE

SSNLF

TCNNF

TLRY

UBER

VREOF

VWAGY

VWAPY

WING

Earnings

Health Care

Press Releases

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

News

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Management

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways to announce second quarter financial results on August 1, 2024

Compass Pathways announces second quarter 2024 financial results and business highlights

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways to participate in three investor conferences in September

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

COLL

Absci

Akebia Therapeutics

Alector

Altimmune

Anika Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Biomea Fusion

C4 Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

GRAIL

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

MeiraGTx Hldgs

Organogenesis Hldgs

Prime Medicine

Regenxbio

Sage Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Tevogen Bio Holdings

Valneva

Verve Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

RBC Capital

HC Wainwright & Co.

Canaccord Genuity

Morgan Stanley

Deutsche Bank

Comments

Compass Pathways

Noticias

Últimas noticias sobre Compass Pathways (NASDAQ:CMPS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL